The Genetic Testing Market is projected to reach $ 28.24 billion by 2030, at a CAGR of 10.4% from 2023 to 2030. Genetic testing involves the analysis of chromosomes, proteins, and certain metabolites to detect heritable disease-related genotypes, mutations, phenotypes, or karyotypes for clinical purposes. Genetic testing can be done for various applications, including prenatal testing, predictive and presymptomatic testing, diagnostic testing, carrier testing, and preimplantation testing. They are usually done using high throughput sequencing technology like next-generation sequencing.
A growing number of tests are being developed to analyze multiple genes that may increase or decrease a person’s risk of diseases, such as cancer or diabetes. Such tests and other applications of genomic technologies have the potential to help prevent common diseases and improve the health of individuals and populations.
The growth of this market is mainly driven by government initiatives promoting genetic testing, the increasing prevalence of genetic disorders, a growing need for the early detection & prevention of diseases, the increasing applications of genetic testing in oncology, and the decreasing costs of sequencing procedures. However, the high cost of genetic testing in low-income countries and the social and ethical implications of genetic testing restrain the growth of the genetic testing market.
The growing potential of direct-to-consumer genetic testing and the emerging field of genetic counseling are expected to create growth opportunities for the players operating in this market. However, the low chances of positive, actionable mutations and concerns regarding the security & privacy of genetic data are major challenges to market growth.
The Impact of COVID-19 on the Genetic Testing Market
The outbreak of COVID-19 in March 2020 was a public health crisis and led to nationwide lockdowns and restrictions in many countries worldwide. The majority of the health services & resources were diverted to prioritizing COVID-19. Similarly, laboratory resources and skilled personnel for genetic and genomic testing were directed toward fighting the COVID-19 pandemic. The volume of genetic testing decreased during the pandemic due to growing cases of infections due to its variants like Delta and Omicron. The pandemic negatively impacted the demand for genetic testing due to the prioritization of healthcare resources for COVID-19.
The stringent lockdowns and restrictions led to supply chain disruption leading to delays in delivering the laboratory reagents and equipment. These factors impacted the growth of the market to a certain extent; however, the market is gaining traction as the situation is normalizing. Countries around the world enhanced their genomics capabilities during the pandemic to identify the spread of the virus. The COVID-19 pandemic has increased the adoption of advanced technologies such as NGS for various applications, including epidemiology, metagenomic analysis, and diagnostics. The widespread adoption of enhanced genomic technologies by many countries around the world offers a great opportunity for the genetic testing market.
Click here to: Get Free Sample Pages of this Report
Increasing Applications of Genetic Testing in Oncology to Drive Market Growth
Cancer is a genome disease, and major strides have been made in understanding and treating this heterogeneous collection of diseases. This comprises the initial identification of oncogenes and tumor suppressor genes for the development of the first generation of targeted therapies, culminating in the full annotation of the genomic landscape of the most common cancer types.
The global prevalence of cancer is expected to increase from 19.2 million new cases in 2020 to 24.0 million new cases in 2030, as per International Agency for Research on Cancer. Also, the mortalities from cancer are expected to increase from 9.9 million deaths in 2020 to 12.9 million deaths in 2030. Oncology biomarkers can provide affordable, reliable, accurate, non-invasive, and sensitive information to help effectively manage cancer. Early cancer detection can lead to positive results.
Sequencing technologies like NGS are increasingly used for genetic profiling in targeted cancer therapy applications due to the decreasing costs and turnaround time of NGS, improvements in bioinformatics analyses, and the harmonization of the knowledge base to facilitate the clinical interpretation of genetic results.
Growing Potential of Direct-to-Consumer Genetic Testing to Offer Growth Opportunities for the Market
Direct-to-consumer genetic testing (DCGT) allows individuals to gain a deeper understanding of their genetic information without involving their physicians. This area is growing majorly due to consumers’ increasing awareness about the links between genetics and diseases, enhancing the evolution of patients' health, and precision medicine designed around individual genetic profiles. For accurate genetic testing, companies are working to improve the detection of carrier status and ease of consumer use.
In recent years, the number of DTC genetic tests performed has increased significantly and is expected to show strong growth in the future. Moreover, growing consumer use and subsequent follow-up with healthcare providers and insurers can be further anticipated to propel the growth of DTC genetic testing.
Key Findings of the Genetic testing market Study:
In 2023, the Consumables & Reagents Segment is Expected to Account for the Largest Share of the Genetic Testing Market
Based on offering, the genetic testing market is segmented into consumables & reagents, instruments, and services. In 2023, the consumables & reagents segment is expected to account for the largest share of the genetic testing market. The large market share of this segment is attributed to the recurring purchase of reagents and kits, new launches of kits & reagents, and increased demand for clinical diagnostics tests for diagnostic testing, prenatal testing, newborn screening, preimplantation testing, and other applications.
In 2023, the Prenatal Testing Segment is Expected to Account for the Largest Share of the Genetic Testing Market
Based on test type, the genetic testing market is segmented into prenatal testing, predictive and presymptomatic testing, diagnostic testing, carrier testing, newborn screening, and preimplantation testing. In 2023, the prenatal testing segment is expected to account for the largest share of the genetic testing market. Prenatal testing detects whether the fetus has any abnormalities, such as certain hereditary or spontaneous genetic disorders. Also, prenatal testing is currently the best way to understand the genetic risk associated with an infant’s health. Due to this, its use is increasing rapidly in developed and developing countries.
In 2023, the Molecular Tests Segment is Expected to Account for the Largest Share of the Genetic Testing Market
Based on method, the genetic testing market is segmented into molecular tests, chromosomal tests, and biochemical tests. In 2023, the molecular tests segment is expected to account for the largest share of the genetic testing market. Molecular tests vary in scope and include a targeted single variant, single gene, gene panel, and whole exome sequencing/whole genome sequencing. The large market share of this segment is attributed to factors such as advancements in technology and the ability to perform sequencing at single nucleotide resolution with cheaper, faster, and with the utmost accuracy by using whole genome sequencing (WGS) and whole exome sequencing (WES) technology.
In 2023, the Hospitals & Clinics Segment is Expected to Account for the Largest Share of the Genetic Testing Market
Based on end user, the genetic testing market is segmented into hospitals & clinics, diagnostic laboratories, and other end users. In 2023, the hospitals & clinics segment is expected to account for the largest share of the genetic testing market. The large market share of this segment is attributed to factors such as the increased utilization of advanced sequencing technologies in hospitals and the increasing adoption of genetic tests for the early-stage detection, diagnosis, and treatment of rare and common diseases across the globe.
Asia-Pacific: The Fastest-growing Market
Asia-Pacific is slated to register the highest growth rate in the genetic testing market during the forecast period. The growth of this Asia-Pacific is driven by the advancing healthcare infrastructure in the region, a large patient pool coupled with the growing adoption of advanced genomics technologies, the growing prevalence of various chronic diseases, and the increasing affordability of genomic testing.
Key Players
The report includes a competitive landscape based on an extensive assessment of product portfolio, test type, method, end user, geographic presence, and the key growth strategies adopted by leading market players in the industry in the last three to four years. The key players profiled in the genetic testing market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), OPKO Health Inc. (U.S.), Natera, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Myriad Genetics, Inc. (U.S.), Centogene N.V. (Germany), Konica Minolta, Inc. (Japan), Fulgent Genetics, Inc. (U.S.), and Laboratory Corporation of America Holdings (U.S.).
Scope of the Report:
Genetic Testing Market, by Offering
Genetic Testing Market, by Test Type
Genetic Testing Market, by Method
Genetic Testing Market, by End User
Genetic Testing Market, by Geography
Key questions answered in the report:
The genetic testing market report covers the market sizes & forecasts based on offering, test type, method, end user, and geography. The genetic testing market studied in this report involves the value analysis of various segments and subsegments of the genetic testing market at the regional and country levels.
The genetic testing market is projected to reach $ 28.24 billion by 2030, at a CAGR of 10.4% during the forecast period of 2023–2030.
The genetic testing market is segmented into consumables & reagents, instruments, and services. In 2023, the consumables & reagents segment is expected to account for the largest share of the genetic testing market due to recurring demand for assays, reagents & consumables and high demand for genetic diagnostic testing.
The genetic testing market is segmented into diagnostic testing, predictive and presymptomatic testing, newborn screening, prenatal testing, preimplantation testing, and carrier testing. In 2023, the prenatal testing segment is expected to account for the largest share of the genetic testing market due to the high prevalence of various chronic diseases, increased demand for early disease diagnosis, and increased awareness among patients.
The genetic testing market is segmented into molecular tests, chromosomal tests, and biochemical tests. In 2023, the molecular tests segment is expected to account for the largest share of the genetic testing market due to high accuracy, wide applicability, and ability to perform sequencing at a single nucleotide level.
The genetic testing market is segmented into hospitals & clinics, diagnostic laboratories, and other end users. In 2023, the hospitals & clinics segment is expected to account for the largest share of the genetic testing market due to the high number of hospitalized patients, increased preference for genetic testing, and advanced healthcare infrastructure in hospitals.
The growth of this market is mainly driven by government initiatives promoting genetic testing, the increasing prevalence of genetic disorders, a growing need for the early detection & prevention of diseases, the increasing applications of genetic testing in oncology, and the decreasing costs of sequencing procedures. Also, the growing potential of direct-to-consumer genetic testing and the emerging field of genetic counseling are expected to create growth opportunities for players in this market. However, the low chances of positive, actionable mutations and concerns regarding the security & privacy of genetic data are major challenges to market growth.
The high cost of genetic testing in low-income countries and the social and ethical implications of genetic testing are restraining the growth of the genetic testing market.
The key players operating in the genetic testing market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), OPKO Health Inc. (U.S.), Natera, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Myriad Genetics, Inc. (U.S.), Centogene N.V. (Germany), Konica Minolta, Inc. (Japan), Fulgent Genetics, Inc. (U.S.), and Laboratory Corporation of America Holdings (U.S.).
The Asia-Pacific region is slated to witness the highest growth rate during the forecast period and offer significant growth opportunities for the players operating in this market. The growth of this market is driven by the large patient pool, advancing healthcare infrastructure, increasing disposable income of the patients, rising prevalence of chronic diseases, and accelerating economic growth of many countries in this region.
This report provides pre & post COVID-19 market estimates.
1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-up Approach
2.3.1.2. Top-down Approach
2.3.1.3. Growth Forecast
2.4. Assumptions for the study
2.5. Limitations for the study
3. Executive Summary
4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. Government Initiatives Promoting Genetic Testing
4.2.2. Increasing Prevalence of Genetic Disorders
4.2.2.1. Sickle Cell Disease
4.2.2.2. Cystic Fibrosis
4.2.2.3. Down Syndrome and Neural Tube Defects
4.2.2.4. Parkinson’s Disease and Alzheimer's Disease
4.2.2.5. Diabetes
4.2.3. Growing Need for the Early Detection & Prevention of Diseases
4.2.4. Increasing Applications of Genetic Testing in Oncology
4.2.5. Decreasing Costs of Sequencing Procedures
4.3. Restraints
4.3.1. High Cost of Genetic Testing in Low-Income Countries
4.3.2. Social and Ethical Implications of Genetic Testing
4.4. Opportunities
4.4.1. Growing Potential of Direct-To-Consumer Genetic Testing
4.4.2. Emerging Field of Genetic Counseling
4.5. Challenges
4.5.1. Low Chances of Positive, Actionable Mutations
4.5.2. Concerns Regarding the Security & Privacy of Genetic Data
5. Global Genetic Testing Market, by Offering
5.1. Introduction
5.2. Consumables & Reagents
5.3. Instruments
5.4. Services
6. Global Genetic Testing Market, by Test Type
6.1. Introduction
6.2. Prenatal Testing
6.3. Predictive and Presymptomatic Testing
6.4. Diagnostic Testing
6.5. Carrier Testing
6.6. Newborn Screening
6.7. Preimplantation Testing
7. Global Genetic Testing Market, by Method
7.1. Introduction
7.2. Molecular Tests
7.3. Chromosomal Tests
7.4. Biochemical Tests
8. Global Genetic Testing Market, by End User
8.1. Introduction
8.2. Hospitals and Clinics
8.3. Diagnostic Laboratories
8.4. Other End Users
9. Genetic Testing Market, by Geography
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. Italy
9.3.3. France
9.3.4. U.K.
9.3.5. Spain
9.3.6. Rest of Europe (RoE)
9.4. Asia-pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Rest of Asia-Pacific (RoAPAC)
9.5. Latin America
9.6. Middle East & Africa
10. Competitive Landscape
10.1. Introduction
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Market Share Analysis (2022)
10.4.1. Illumina, Inc.
10.4.2. Laboratory Corporation of America Holdings
10.4.3. Thermo Fisher Scientific Inc.
10.4.4. Myriad Genetics, Inc.
10.5. Competitive Dashboard
10.5.1. Industry Leaders
10.5.2. Market Differentiators
10.5.3. Vanguards
10.5.4. Emerging Companies
11. Company profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments)
11.1. Thermo Fisher Scientific Inc.
11.2. Illumina, Inc.
11.3. Laboratory Corporation of America Holdings
11.4. Myriad Genetics, Inc.
11.5. Natera, Inc.
11.6. Perkinelmer Inc.
11.7. F. Hoffman-La Roche Ltd.
11.8. Centogene N.V.
11.9. Konica Minolta, Inc.
11.10. Opko Health, Inc.
11.11. Fulgent Genetics, Inc.
12. Appendix
12.1. Available Customization
12.2. Related Reports
List of Tables
Table 1 Global Genetic Testing Market: Impact Analysis of Market Drivers (2023–2030)
Table 2 The Middle East: Cystic Fibrosis Birth Incidence, by Country (2018)
Table 3 Europe: Number of Patients with Cystic Fibrosis, by Country (2020)
Table 4 Asia-Pacific: Number of New Cancer Cases, by Country (2020 Vs. 2030)
Table 5 Number of New Cancer Cases, by Type (2020 Vs. 2030)
Table 6 Global Genetic Testing Market: Impact Analysis of Market Restraints (2023–2030)
Table 7 Global Genetic Testing Market: Impact Analysis of Market Opportunities (2023–2030)
Table 8 Global Genetic Testing Market: Impact Analysis of Market Challenges (2023–2030)
Table 9 Global Genetic Testing Market Size, by Offering, 2021–2030 (USD Million)
Table 10 Global Genetic Testing Market Size for Consumables & Reagents, by Country/Region, 2021–2030 (USD Million)
Table 11 Global Genetic Testing Market Size for Instruments, by Country/Region, 2021–2030 (USD Million)
Table 12 Global Genetic Testing Market Size for Services, by Country/Region, 2021–2030 (USD Million)
Table 13 Global Genetic Testing Market Size, by Test Type, 2021–2030 (USD Million)
Table 14 Global Prenatal Genetic Testing Market Size, by Country/Region, 2021–2030 (USD Million)
Table 15 Global Predictive and Presymptomatic Testing Market Size, by Country/Region, 2021–2030 (USD Million)
Table 16 Global Genetic Diagnostic Testing Market Size, by Country/Region, 2021–2030 (USD Million)
Table 17 Global Carrier Testing Market Size, by Country/Region, 2021–2030 (USD Million)
Table 18 Global Genetic Testing Market Size for Newborn Screening, by Country/Region, 2021–2030 (USD Million)
Table 19 Global Preimplantation Genetic Testing Market Size, by Country/Region, 2021–2030 (USD Million)
Table 20 Global Genetic Testing Market Size, by Method, 2021–2030 (USD Million)
Table 21 Global Molecular Genetic Testing Market Size, by Country/Region, 2021–2030 (USD Million)
Table 22 Global Chromosomal Genetic Testing Market Size, by Country/Region, 2021–2030 (USD Million)
Table 23 Global Biochemical Genetic Testing Market Size, by Country/Region, 2021–2030 (USD Million)
Table 24 Global Genetic Testing Market Size, by End User, 2021–2030 (USD Million)
Table 25 Global Genetic Testing Market Size for Hospitals and Clinics, by Country/Region, 2021–2030 (USD Million)
Table 26 Global Genetic Testing Market Size for Diagnostic Laboratories, by Country/Region, 2021–2030 (USD Million)
Table 27 Global Genetic Testing Market Size for Other End Users, by Country/Region, 2021–2030 (USD Million)
Table 28 Global Genetic Testing Market Size, by Country/Region, 2021–2030 (USD Million)
Table 29 North America: Genetic Testing Market Size, by Country, 2021–2030 (USD Million)
Table 30 North America: Genetic Testing Market Size, by Offering, 2021–2030 (USD Million)
Table 31 North America: Genetic Testing Market Size, by Test Type, 2021–2030 (USD Million)
Table 32 North America: Genetic Testing Market Size, by Method, 2021–2030 (USD Million)
Table 33 North America: Genetic Testing Market Size, by End User, 2021–2030 (USD Million)
Table 34 U.S.: Genetic Testing Market Size, by Offering, 2021–2030 (USD Million)
Table 35 U.S.: Genetic Testing Market Size, by Test Type 2021–2030 (USD Million)
Table 36 U.S.: Genetic Testing Market Size, by Method, 2021–2030 (USD Million)
Table 37 U.S.: Genetic Testing Market Size, by End User, 2021–2030 (USD Million)
Table 38 Canada: Genetic Testing Market Size, by Offering, 2021–2030 (USD Million)
Table 39 Canada: Genetic Testing Market Size, by Test Type 2021–2030 (USD Million)
Table 40 Canada: Genetic Testing Market Size, by Method, 2021–2030 (USD Million)
Table 41 Canada: Genetic Testing Market Size, by End User, 2021–2030 (USD Million)
Table 42 Europe: Genetic Testing Market Size, by Country, 2021–2030 (USD Million)
Table 43 Europe: Genetic Testing Market Size, by Offering, 2021–2030 (USD Million)
Table 44 Europe: Genetic Testing Market Size, by Test Type, 2021–2030 (USD Million)
Table 45 Europe: Genetic Testing Market Size, by Method 2021–2030 (USD Million)
Table 46 Europe: Genetic Testing Market Size, by End User, 2021–2030 (USD Million)
Table 47 Germany: Genetic Testing Market Size, by Offering, 2021–2030 (USD Million)
Table 48 Germany: Genetic Testing Market Size, by Test Type 2021–2030 (USD Million)
Table 49 Germany: Genetic Testing Market Size, by Method, 2021–2030 (USD Million)
Table 50 Germany: Genetic Testing Market Size, by End User 2021–2030 (USD Million)
Table 51 Italy: Genetic Testing Market Size, by Offering, 2021–2030 (USD Million)
Table 52 Italy: Genetic Testing Market Size, by Test Type, 2021–2030 (USD Million)
Table 53 Italy: Genetic Testing Market Size, by Method, 2021–2030 (USD Million)
Table 54 Italy.: Genetic Testing Market Size, by End User, 2021–2030 (USD Million)
Table 55 France: Genetic Testing Market Size, by Offering, 2021–2030 (USD Million)
Table 56 France: Genetic Testing Market Size, by Test Type 2021–2030 (USD Million)
Table 57 France: Genetic Testing Market Size, by Method, 2021–2030 (USD Million)
Table 58 France: Genetic Testing Market Size, by End User, 2021–2030 (USD Million)
Table 59 U.K.: Genetic Testing Market Size, by Offering, 2021–2030 (USD Million)
Table 60 U.K.: Genetic Testing Market Size, by Test Type, 2021–2030 (USD Million)
Table 61 U.K.: Genetic Testing Market Size, by Method, 2021–2030 (USD Million)
Table 62 U.K.: Genetic Testing Market Size, by End User 2021–2030 (USD Million)
Table 63 Spain: Genetic Testing Market Size, by Offering, 2021–2030 (USD Million)
Table 64 Spain: Genetic Testing Market Size, by Test Type, 2021–2030 (USD Million)
Table 65 Spain: Genetic Testing Market Size, by Method, 2021–2030 (USD Million)
Table 66 Spain: Genetic Testing Market Size, by End User, 2021–2030 (USD Million)
Table 67 Estimated Number of New Cancer Cases (2030)
Table 68 Rest of Europe: Genetic Testing Market Size, by Offering, 2021–2030 (USD Million)
Table 69 Rest of Europe: Genetic Testing Market Size, by Test Type 2021–2030 (USD Million)
Table 70 Rest of Europe: Genetic Testing Market Size, by Method 2021–2030 (USD Million)
Table 71 Rest of Europe: Genetic Testing Market, by End User 2021–2030 (USD Million)
Table 72 Asia-Pacific: Genetic Testing Market Size, by Country, 2021–2030 (USD Million)
Table 73 Asia-Pacific: Genetic Testing Market Size, by Offering, 2021–2030 (USD Million)
Table 74 Asia-Pacific: Genetic Testing Market Size, by Test Type, 2021–2030 (USD Million)
Table 75 Asia-Pacific: Genetic Testing Market Size, by Method, 2021–2030 (USD Million)
Table 76 Asia-Pacific: Genetic Testing Market Size, by End User. 2021–2030 (USD Million)
Table 77 Japan: Genetic Testing Market Size, by Offering, 2021–2030 (USD Million)
Table 78 Japan: Genetic Testing Market Size, by Test Type 2021–2030 (USD Million)
Table 79 Japan: Genetic Testing Market Size, by Method, 2021–2030 (USD Million)
Table 80 Japan: Genetic Testing Market Size, by End User, 2021–2030 (USD Million)
Table 81 China: Genetic Testing Market Size, by Offering, 2021–2030 (USD Million)
Table 82 China: Genetic Testing Market Size, by Test Type, 2021–2030 (USD Million)
Table 83 China: Genetic Testing Market Size, by Method, 2021–2030 (USD Million)
Table 84 China: Genetic Testing Market Size, by End User, 2021–2030 (USD Million)
Table 85 India: Genetic Testing Market Size, by Offering, 2021–2030 (USD Million)
Table 86 India: Genetic Testing Market Size, by Test Type, 2021–2030 (USD Million)
Table 87 India: Genetic Testing Market Size, by Method, 2021–2030 (USD Million)
Table 88 India: Genetic Testing Market Size, by End User, 2021–2030 (USD Million)
Table 89 Estimated Number of New Cancer Cases in the Rest of Asia-Pacific, by Country (2020 Vs. 2030)
Table 90 Rest of Asia-Pacific: Genetic Testing Market Size, by Offering, 2021–2030 (USD Million)
Table 91 Rest of Asia-Pacific: Genetic Testing Market Size, by Test Type, 2021–2030 (USD Million)
Table 92 Rest of Asia-Pacific: Genetic Testing Market Size, by Method, 2021–2030 (USD Million)
Table 93 Rest of Asia-Pacific: Genetic Testing Market Size, by End User, 2021–2030 (USD Million)
Table 94 Latin America: Genetic Testing Market Size, by Offering, 2021–2030 (USD Million)
Table 95 Latin America: Genetic Testing Market Size, by Test Type, 2021–2030 (USD Million)
Table 96 Latin America: Genetic Testing Market Size, by Method, 2021–2030 (USD Million)
Table 97 Latin America: Genetic Testing Market Size, by End User, 2021–2030 (USD Million)
Table 98 Cystic Fibrosis Birth Incidence in The Middle East
Table 99 Middle East and Africa: Genetic Testing Market Size, by Offering, 2021–2030 (USD Million)
Table 100 Middle East and Africa: Genetic Testing Market Size, by Test Type, 2021–2030 (USD Million)
Table 101 Middle East and Africa: Genetic Testing Market Size, by Method, 2021–2030 (USD Million)
Table 102 Middle East and Africa: Genetic Testing Market Size, by End User, 2021–2030 (USD Million)
Table 103 Recent Developments, by Company, 2019-2023
List of Figures
Figure 1 Key Stakeholders
Figure 2 Research Process
Figure 3 Key Secondary Sources
Figure 4 Primary Research Techniques
Figure 5 Key Executives Interviewed
Figure 6 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 7 Market Size Estimation
Figure 8 Global Genetic Testing Market Size, by Offering, 2023 Vs. 2030 (USD Million)
Figure 9 Global Genetic Testing Market Size, by Test Type, 2023 Vs. 2030 (USD Million)
Figure 10 Global Genetic Testing Market Size, by Method, 2023 Vs. 2030 (USD Million)
Figure 11 Global Genetic Testing Market Size, by End User, 2023 Vs. 2030 (USD Million)
Figure 12 Global Genetic Testing Market Size, by Geography
Figure 13 Market Dynamics: Genetic Testing Market
Figure 14 Number of Cancer Cases, by Region (2020)
Figure 15 U.S.: Increase in Cancer Cases (2017–2022)
Figure 16 Genome Sequencing Costs, 2010–2021 (USD/Genome)
Figure 17 Global Genetic Testing Market Size, by Offering, 2021 Vs. 2030 (USD Million)
Figure 18 Global Genetic Testing Market Size, by Test Type, 2021 Vs. 2030 (USD Million)
Figure 19 Global Genetic Testing Market Size, by Method, 2021 Vs. 2030 (USD Million)
Figure 20 Global Genetic Testing Market Size, by End User, 2021 Vs. 2030 (USD Million)
Figure 21 Global Genetic Testing Market, by Region, 2023 Vs. 2030 (USD Million)
Figure 22 North America: Genetic Testing Market Snapshot
Figure 23 Europe: Genetic Testing Market Snapshot
Figure 24 Germany: Estimated Cancer Incidence 2020 Vs. 2030 Percentage Distribution, by Age Group (0–44 Years)
Figure 25 Italy: Estimated Cancer Incidence 2020 Vs. 2030 Percentage Distribution by Age Group (0–44 Years)
Figure 26 France: Estimated Incidence In 2020 And 2030 by Cancer Percentage Distribution, by Age Group (0–44 Years)
Figure 27 Health Expenditure (2015–2020)
Figure 28 Asia-Pacific: Genetic Testing Market Snapshot
Figure 29 Number of New Cancer Cases, by Country/Region (2020)
Figure 30 Key Growth Strategies Adopted by Leading Players, 2019–2023
Figure 31 Genetic Testing Market: Competitive Benchmarking, by Offering
Figure 32 Genetic Testing Market: Competitive Benchmarking, by Region
Figure 33 Global Genetic Testing Market Share Analysis, by Key Players, 2022(%)
Figure 34 Competitive Dashboard: Genetic Testing Market
Figure 35 Thermo Fisher Scientific Inc.: Financial Overview (2021)
Figure 36 Illumina, Inc.: Financial Overview (2021)
Figure 37 Laboratory Corporation of America Holdings: Financial Overview (2021)
Figure 38 Myriad Genetics, Inc.: Financial Overview (2021)
Figure 39 Natera, Inc.: Financial Overview (2021)
Figure 40 Perkinelmer Inc.: Financial Overview (2021)
Figure 41 F. Hoffmann-La Roche Ltd.: Financial Overview (2021)
Figure 42 Centogene N.V.: Financial Overview (2021)
Figure 43 Konica Minolta, Inc.: Financial Overview (2021)
Figure 44 Opko Health, Inc.: Financial Overview (2021)
Figure 45 Fulgent Genetics, Inc.: Financial Overview (2021)
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Feb-2023
Published Date: Jan-2023
Published Date: Oct-2022
Published Date: Nov-2021
